Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03326973 · ClinicalTrials.gov registry record
Long-Term Quality of Life in Patients With Metastatic Melanoma Treated With Checkpoint Inhibitors
A clinical trial, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- 107
- Enrollment target
NCT03326973: Completed study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT03326973 is a clinical trial that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 107 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03326973 has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- 107 participants
- Enrollment target
Study Summary
To identify and describe long-term quality of life (QOL) issues in patients with metastatic melanoma treated with checkpoint inhibitors who achieved cancer control for a minimum of 12 months and remain on maintenance checkpoint inhibitor therapy.
Interventions
- BEHAVIORAL EuroQoL EQ-5D-3L
- BEHAVIORAL EORTC QLQ-C30
- OTHER PRO-CTCAE
- BEHAVIORAL Fatigue severity score questionnaire
- BEHAVIORAL The COST
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 107 participants |
| Start Date | 2017-10-25 |
| Est. Completion | 2020-12-14 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03326973
The ClinicalTrials.gov registry entry for NCT03326973 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 107 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which EuroQoL EQ-5D-3L is the first listed.
NCT03326973 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03326973 about?
NCT03326973 is a clinical study titled "Long-Term Quality of Life in Patients With Metastatic Melanoma Treated With Checkpoint Inhibitors". To identify and describe long-term quality of life (QOL) issues in patients with metastatic melanoma treated with checkpoint inhibitors who achieved cancer control for a minimum of 12 months and remain on maintenance checkpoint inhibitor therapy.
What is the current status of trial NCT03326973?
This trial is currently completed. The enrollment target is 107 participants. The study started on 2017-10-25. Estimated completion is 2020-12-14.
What interventions are being tested in trial NCT03326973?
The interventions under investigation include: EuroQoL EQ-5D-3L (BEHAVIORAL), EORTC QLQ-C30 (BEHAVIORAL), PRO-CTCAE (OTHER), Fatigue severity score questionnaire (BEHAVIORAL), The COST (BEHAVIORAL).
Who is sponsoring clinical trial NCT03326973?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.